Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Greenspan

Showing results (11-20 of 31) with videos related to

Pageof 4
Sort By:
Supportive Cancer Therapy|July 17, 2008
A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapyRomeo A Mandanas, Roy Beveridge, Robert M Rifkin, et al.
International Psychogeriatrics|October 6, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychoticsSanford Finkel, Chris Kozma, Stacey Long, et al.
The Journal of Clinical Psychiatry|October 20, 2004
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidoneJonathan Rabinowitz, Ira R Katz, Peter Paul De Deyn, et al.
Clinical Neurology and Neurosurgery|June 1, 2005
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidonePeter Paul De Deyn, Ira R Katz, Henry Brodaty, et al.
International Journal of Geriatric Psychiatry|November 30, 2005
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trialHenry Brodaty, David Ames, John Snowdon, et al.
Current Medical Research and Opinion|October 4, 2007
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorderMarcia F T Rupnow, Andrew Greenspan, Georges M Gharabawi, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 1, 2006
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trialJacobo Mintzer, Andrew Greenspan, Ivo Caers, et al.
The Journal of Clinical Psychiatry|January 24, 2006
Methodological issues in a comparative study of ziprasidone and risperidoneGeorges M Gharabawi, Cynthia A Bossie, Ramy Mahmoud, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 12, 2007
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depressionGeorge S Alexopoulos, Carla M Canuso, Georges M Gharabawi, et al.
Rheumatology and Therapy|August 21, 2021
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE StudyJeffrey R Curtis, Soumya D Chakravarty, Shawn Black, et al.
Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:
Pageof 4
Supportive Cancer Therapy|July 17, 2008
A randomized, multicenter, open-label comparison of the antiemetic efficacy of dolasetron versus ondansetron for the prevention of nausea and vomiting during high-dose myeloablative chemotherapyRomeo A Mandanas, Roy Beveridge, Robert M Rifkin, et al.
International Psychogeriatrics|October 6, 2005
Risperidone treatment in elderly patients with dementia: relative risk of cerebrovascular events versus other antipsychoticsSanford Finkel, Chris Kozma, Stacey Long, et al.
The Journal of Clinical Psychiatry|October 20, 2004
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidoneJonathan Rabinowitz, Ira R Katz, Peter Paul De Deyn, et al.
Clinical Neurology and Neurosurgery|June 1, 2005
Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidonePeter Paul De Deyn, Ira R Katz, Henry Brodaty, et al.
International Journal of Geriatric Psychiatry|November 30, 2005
Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trialHenry Brodaty, David Ames, John Snowdon, et al.
Current Medical Research and Opinion|October 4, 2007
Incidence and costs of polypharmacy: data from a randomized, double-blind, placebo-controlled study of risperidone and quetiapine in patients with schizophrenia or schizoaffective disorderMarcia F T Rupnow, Andrew Greenspan, Georges M Gharabawi, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 1, 2006
Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trialJacobo Mintzer, Andrew Greenspan, Ivo Caers, et al.
The Journal of Clinical Psychiatry|January 24, 2006
Methodological issues in a comparative study of ziprasidone and risperidoneGeorges M Gharabawi, Cynthia A Bossie, Ramy Mahmoud, et al.
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|October 12, 2007
Placebo-controlled study of relapse prevention with risperidone augmentation in older patients with resistant depressionGeorge S Alexopoulos, Carla M Canuso, Georges M Gharabawi, et al.
Rheumatology and Therapy|August 21, 2021
Incidence of Infusion Reactions and Clinical Effectiveness of Intravenous Golimumab Versus Infliximab in Patients with Rheumatoid Arthritis: The Real-World AWARE StudyJeffrey R Curtis, Soumya D Chakravarty, Shawn Black, et al.
Pageof 4